CN119212731A - 用于靶向表达Trop-2的肿瘤的抗体缀合物 - Google Patents
用于靶向表达Trop-2的肿瘤的抗体缀合物 Download PDFInfo
- Publication number
- CN119212731A CN119212731A CN202380028866.0A CN202380028866A CN119212731A CN 119212731 A CN119212731 A CN 119212731A CN 202380028866 A CN202380028866 A CN 202380028866A CN 119212731 A CN119212731 A CN 119212731A
- Authority
- CN
- China
- Prior art keywords
- group
- antibody
- hetero
- moiety
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22163943 | 2022-03-23 | ||
| EP22163943.8 | 2022-03-23 | ||
| PCT/EP2023/057561 WO2023180485A1 (en) | 2022-03-23 | 2023-03-23 | Antibody-conjugates for targeting of tumours expressing trop-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119212731A true CN119212731A (zh) | 2024-12-27 |
Family
ID=81308125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380028866.0A Pending CN119212731A (zh) | 2022-03-23 | 2023-03-23 | 用于靶向表达Trop-2的肿瘤的抗体缀合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250090679A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4496594A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025510700A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20250024743A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119212731A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023241225A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3253220A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL315207A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024011520A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023180485A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3876998A1 (en) | 2018-11-05 | 2021-09-15 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939255A (en) | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| CA2235269C (en) | 1995-10-19 | 2006-09-19 | Bristol-Myers Squibb Company | Monoclonal antibody br110 and uses thereof |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| US20070249014A1 (en) | 2006-02-10 | 2007-10-25 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2009102820A2 (en) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Modified sugar substrates and methods of use |
| JP2012516887A (ja) | 2009-02-05 | 2012-07-26 | オンコックス・エッセ・エッレ・エッレ | 抗trop−2モノクローナル抗体ならびに腫瘍の治療および診断におけるその使用 |
| WO2011155579A1 (ja) | 2010-06-10 | 2011-12-15 | 北海道公立大学法人札幌医科大学 | 抗Trop-2抗体 |
| SG11201401699WA (en) | 2011-11-11 | 2014-09-26 | Rinat Neuroscience Corp | Antibodies specific for trop-2 and their uses |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| EP3177633B1 (en) | 2014-08-04 | 2022-07-20 | SynAffix B.V. | Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
| EP3733209A1 (en) | 2014-10-03 | 2020-11-04 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
| CN107810273B (zh) | 2015-04-23 | 2022-09-27 | 西纳福克斯股份有限公司 | 用为或衍生自β-(1,4)-N-乙酰半乳糖胺转移酶的糖基转移酶修饰糖蛋白的方法 |
| CA3026651A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
| TWI920652B (zh) | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| EP3876998A1 (en) * | 2018-11-05 | 2021-09-15 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| KR20240104214A (ko) | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| RS64961B1 (sr) | 2019-04-26 | 2024-01-31 | Immunogen Inc | Derivati kamptotecina |
| KR20230021018A (ko) | 2020-06-05 | 2023-02-13 | 재단법인 생물기술개발중심 | 항-메조텔린 항체를 함유하는 항체-약물 컨쥬게이트 및 이의 용도 |
| NL2026947B1 (en) | 2020-11-20 | 2022-07-01 | Synaffix Bv | Tyrosine-based antibody conjugates |
| CN113816969B (zh) | 2021-04-30 | 2024-01-16 | 联宁(苏州)生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
| US12533419B2 (en) | 2021-07-19 | 2026-01-27 | Mabplex International Co., Ltd. | Antibody drug conjugate loaded with binary toxins and its application |
-
2023
- 2023-03-23 CA CA3253220A patent/CA3253220A1/en active Pending
- 2023-03-23 AU AU2023241225A patent/AU2023241225A1/en active Pending
- 2023-03-23 EP EP23714682.4A patent/EP4496594A1/en active Pending
- 2023-03-23 WO PCT/EP2023/057561 patent/WO2023180485A1/en not_active Ceased
- 2023-03-23 JP JP2024556005A patent/JP2025510700A/ja active Pending
- 2023-03-23 CN CN202380028866.0A patent/CN119212731A/zh active Pending
- 2023-03-23 KR KR1020247034725A patent/KR20250024743A/ko active Pending
- 2023-03-23 IL IL315207A patent/IL315207A/en unknown
-
2024
- 2024-09-19 MX MX2024011520A patent/MX2024011520A/es unknown
- 2024-09-20 US US18/892,270 patent/US20250090679A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023241225A1 (en) | 2024-08-29 |
| JP2025510700A (ja) | 2025-04-15 |
| IL315207A (en) | 2024-10-01 |
| MX2024011520A (es) | 2025-01-09 |
| EP4496594A1 (en) | 2025-01-29 |
| US20250090679A1 (en) | 2025-03-20 |
| KR20250024743A (ko) | 2025-02-19 |
| WO2023180485A1 (en) | 2023-09-28 |
| CA3253220A1 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260108620A1 (en) | Antibody-conjugates for targeting of tumours expressing trop-2 | |
| US12440573B2 (en) | Antibody-conjugates for targeting of tumours expressing PTK7 | |
| JP7815223B2 (ja) | 可溶性タグを有する分子および関連方法 | |
| US20250082770A1 (en) | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen | |
| KR102099593B1 (ko) | 항-인간 인터루킨-2 항체 및 이의 용도 | |
| JP2021524852A (ja) | 抗muc1抗体−薬物コンジュゲート | |
| US20250090679A1 (en) | Antibody-conjugates for targeting of tumours expressing trop-2 | |
| US20250312477A1 (en) | Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof | |
| US20210269552A1 (en) | Anti-glyco-muc1 antibodies and their uses | |
| TW202434739A (zh) | 用於抗體藥物複合體工程之糖苷合成酶變體 | |
| US20250205353A1 (en) | Antibody-conjugates for targeting of tumours expressing nectin-4 | |
| JP2025526869A (ja) | アントラサイクリン及びそのコンジュゲート | |
| JP2022552349A (ja) | Bリンパ球特異的アマトキシン抗体コンジュゲート | |
| WO2025140358A1 (en) | A pharmaceutical composition of anti-fgfr3 antibody drug conjugate and applications thereof | |
| HK40094183A (en) | Molecules with solubility tag and related methods | |
| TW202434311A (zh) | 自穩定連接子軛合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |